Biology Reference
In-Depth Information
[97] Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren
BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Im-
munother 2010;59(11):1739-44.
[98] Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study
of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and
breast cancer. Cytotherapy 2011;13(1):98-107.
[99] Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, et al. Suppression of
natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T
cells. Proc Natl Acad Sci U S A 2006;103(14):5460-5.
[100] Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M,
et al. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell
elimination induces effective adaptive antitumor immune responses. J Immunol
2011;186(6):3327-35.
[101] Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells
overcomes inhibitory signals and induces specific killing of leukemic cells. Blood
2005;106(1):376-83.
[102] Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of hu-
man natural killer cells. Br J Haematol 2009;145(5):606-13.
[103] Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al.
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural
killer cells. PLoS One 2012;7(1):e30264.
[104] Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immuno-
globulinlike receptors develop from single hematopoietic stem cells with preferential
expression of NKG2A and KIR2DL2/L3/S2. Blood 2001;98(3):705-13.
[105] Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK
cells acquire functional receptors and cytolytic activity. J Immunol 2005;175(8):5095-103.
[106] Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, et al. KHYG-1, a model for
the study of enhanced natural killer cell cytotoxicity. Exp Hematol 2005;33(10):1160-71.
[107] Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adop-
tive immunotherapy with a natural killer cell line. Int J Radiat Biol 2006;82(5):355-61.
[108] Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the
allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a
phase I trial. Cytotherapy 2008;10(6):625-32.
[109] Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adop-
tive immunotherapy of cancer. Hum Mol Genet 2011;20(R1):R93-9.
[110] Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of gene-
modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol
2008;181(5):3449-55.
[111] Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, et al. 2B4
(CD244) signaling by recombinant antigen-specific chimeric receptors costimulates
natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res
2009;15(15):4857-66.
[112] Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. Preclinical character-
ization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments
natural killer-mediated killing of tumor cells. Blood 2009;114(13):2667-77.
[113] Lin W, Voskens CJ, Zhang X, Schindler DG, Wood A, Burch E, et al. Fc-dependent ex-
pression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137
monoclonal antibodies. Blood 2008;112(3):699-707.
[114] Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of
B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood
1994;83(2):435-45.
[115] Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymor-
phism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoim-
mune disease. J Clin Invest 1997;100(5):1059-70.
[116] Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeu-
tic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc
receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8.
[117] Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: prom-
ises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012;526(2):146-53.
[118] Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, Colonna M, et al.
Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells
inhibits FcR-initiated tyrosine kinase activation. Immunity 1996;5(6):629-38.
[119] Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al.
Stimulation of natural killer cells with a CD137-specific antibody enhances
trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest
2012;122(3):1066-75.
355
Search WWH ::
Custom Search